Cleveland Biolabs Inc. Announces Start of Advanced Cancer Trial for CBLB502

BUFFALO, N.Y., March 12, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the first patient completed an initial series of five doses in a Phase I trial evaluating CBLB502 in advanced cancer patients. The study will evaluate the safety and pharmacokinetic profile of CBLB502 in patients with advanced cancers. Up to forty-eight patients are expected to be enrolled in multiple cohorts to determine the safety, tolerability, and maximum tolerated dose of repeated administrations of CBLB502. Evaluations for evidence of anticancer activity of CBLB502 in advanced cancer patients will also be performed.